截至2026年1月28日收盘，海翔药业(002099)报收于6.35元，上涨1.28%，换手率2.09%，成交量33.69万 手，成交额2.14亿元。 当日关注点 浙江海翔药业股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-13,500万元 至-9,000万元，扣除非经常性损益后的净利润为-14,200万元至-9,500万元，基本每股收益为-0.08元 至-0.06元。与上年同期相比亏损幅度收窄。业绩变动主要原因包括医药板块受产品价格波动、原材料 价格上涨影响，毛利率承压；染料板块核心产品价格上涨，盈利能力修复；美元兑人民币汇率走低对净 利润产生较大负面影响。本业绩预告未经审计，与会计师事务所无重大分歧。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月28日主力资金净流入2552.54万元，散户资金净流出2814.74万元。 来自业绩披露要点：海翔药业预计2025年全年归属净利润亏损9000万元至1.35亿元，亏损幅度较 上年同期收窄。 来自公司公告汇总：海翔药业获地夸磷索钠化学原料药 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of Mirabegron active pharmaceutical ingredient, enhancing the company's product line and market competitiveness [1] Summary by Relevant Sections - **Approval Announcement** - The company announced that it has received the approval notice for the marketing application of Mirabegron active pharmaceutical ingredient [1] - **Product Information** - Mirabegron is a selective β-3 adrenergic receptor agonist primarily used for the treatment of overactive bladder [1] - **Market Data** - According to IMS data, the global consumption of Mirabegron active pharmaceutical ingredient is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - **Strategic Implications** - The approval will enrich the company's active pharmaceutical ingredient product line and enhance its market competitiveness [1]